Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-08-14, Stock:NVS, The news for the past five days is as follows:
2019-08-07: NEWS1: Novartis (NVS) Alert: Johnson Fistel Launches Investigation into Novartis AG; Investors Encouraged to Contact Firm.NEWS2: 2 Marijuana Stocks to Buy Heading into Q2 Earnings and Beyond.NEWS3: INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Novartis AG Investors (NVS).NEWS4: UPDATE 1-Medicare to cover expensive cancer cell therapies.NEWS5: Codexis Rolls Into Second Half Armed with Cash.NEWS6: Codexis Rolls Into Second Half Armed with Cash.NEWS7: Horizon Stock Pops On Beat And Raise As Another Drugmaker Reverses.NEWS8: Mallinckrodt (MNK) Q2 Earnings Beat, Generics Spin-off on Hold.NEWS9: Mallinckrodt (MNK) Q2 Earnings Beat, Generics Spin-off on Hold.NEWS10: Mallinckrodt (MNK) Q2 Earnings Beat, Generics Spin-off on Hold.NEWS11: Conatus (CNAT) Beats on Q2 Earnings, Stops Emricasan Studies.NEWS12: Conatus (CNAT) Beats on Q2 Earnings, Stops Emricasan Studies.NEWS13: Conatus (CNAT) Beats on Q2 Earnings, Stops Emricasan Studies.NEWS14: FDA Investigates Data Manipulation Issue With Newly Approved Novartis Drug Zolgensma.NEWS15: UPDATE 2-Novartis says it knew of Zolgensma data problems before U.S. approval.NEWS16: Novartis says knew about Zolgensma data problems before U.S. approval.NEWS17: Akcea Therapeutics, Inc. (AKCA) Q2 2019 Earnings Call Transcript.NEWS18: The Daily Biotech Pulse: Novartis Stands By Zolgensma, GW Pharma Q2 Propelled By Epidiolex Sales, Ionis-Akcea Clinical Readout.NEWS19: [video]FDA Says Some Data From Novartis Gene Therapy Manipulated.NEWS20: PRESS DIGEST- Financial Times - Aug 7.
2019-08-08: NEWS1: Momenta Continues Its Transition.NEWS2: Momenta Continues Its Transition.NEWS3: Sarepta stock tumbles after Duchenne gene therapy complication.NEWS4: NVS vs. NVO: Which Stock Should Value Investors Buy Now?.NEWS5: NVS vs. NVO: Which Stock Should Value Investors Buy Now?.NEWS6: NVS vs. NVO: Which Stock Should Value Investors Buy Now?.NEWS7: Medicare to cover expensive cancer cell therapies.NEWS8: Glancy Prongay & Murray LLP Announces Investigation on Behalf of Novartis AG Investors (NVS).NEWS9: 2 Marijuana Stocks to Buy Heading into Q2 Earnings and Beyond.NEWS10: 2 Marijuana Stocks to Buy Heading into Q2 Earnings and Beyond.
2019-08-09: NEWS1: Tilray (TLRY) to Report Q2 Earnings: What's in the Cards?.NEWS2: Tilray (TLRY) to Report Q2 Earnings: What's in the Cards?.NEWS3: Intrexon (XON) Reports Narrower-Than-Expected Loss in Q2.NEWS4: Intrexon (XON) Reports Narrower-Than-Expected Loss in Q2.NEWS5: Has Novartis (NVS) Outpaced Other Medical Stocks This Year?.NEWS6: Has Novartis (NVS) Outpaced Other Medical Stocks This Year?.NEWS7: Intrexon (XON) Reports Narrower-Than-Expected Loss in Q2.NEWS8: Tilray (TLRY) to Report Q2 Earnings: What's in the Cards?.NEWS9: Has Novartis (NVS) Outpaced Other Medical Stocks This Year?.
2019-08-12: NEWS1: UPDATE 1-Senator Grassley seeks info on Novartis's Zolgensma data issues.NEWS2: Senator Grassley seeks info on Novartis's Zolgensma data issues.NEWS3: The Biggest Biotech Stock Is Approaching A Breakout — Here's Why.NEWS4: Amgen wins U.S. patent battle on arthritis drug Enbrel.NEWS5: Amgen stock gets boost from Friday ruling on Enbrel.NEWS6: Amgen Wins Enbrel U.S. Patent Litigation Against Novartis.NEWS7: Amgen Wins Enbrel U.S. Patent Litigation Against Novartis.NEWS8: Amgen Wins Enbrel U.S. Patent Litigation Against Novartis.NEWS9: Amgen’s Court Win Could Mark ‘a New Dawn’ for the Stock.NEWS10: [video]Amgen Climbs After Winning Patent Case on Enbrel.NEWS11: Amgen Climbs After Winning Patent Case on Enbrel.NEWS12: 5 Big Pharma Showdowns to Watch.
2019-08-13: NEWS1: Why This IBD Stock Of The Day Is No Longer Sweating $5 Billion In Sales.NEWS2: Here's Why Amgen Stock is Outperforming Its Industry Of Late.NEWS3: Here's Why Amgen Stock is Outperforming Its Industry Of Late.NEWS4: Jazz (JAZZ) Acquires Cavion, Adds Movement Disorder Candidate.NEWS5: Jazz (JAZZ) Acquires Cavion, Adds Movement Disorder Candidate.NEWS6: Jazz (JAZZ) Acquires Cavion, Adds Movement Disorder Candidate.NEWS7: Here's Why Amgen Stock is Outperforming Its Industry Of Late.NEWS8: Pre-Market Most Active for Aug 13, 2019 :  JD, UBS, DCPH, TVIX, NVS, GE, AMD, SQQQ, QQQ, TME, BABA, BE.NEWS9: Pre-Market Most Active for Aug 13, 2019 :  JD, UBS, DCPH, TVIX, NVS, GE, AMD, SQQQ, QQQ, TME, BABA, BE.NEWS10: 5 Biggest New Drugs Approved in 2019 So Far.NEWS11: 5 Biggest New Drugs Approved in 2019 So Far.NEWS12: 5 Biggest New Drugs Approved in 2019 So Far.

Answer: Decrease